November 2025 in “The Journal of Dermatology” This case report describes a 56-year-old Japanese woman with severe atopic dermatitis (AD) and coexisting refractory alopecia areata (AA) who was treated with nemolizumab, an anti-IL-31 receptor A monoclonal antibody. Despite previous unsuccessful treatments for AA, nemolizumab, administered for AD, led to a 90% improvement in the Eczema Area and Severity Index (EASI) score and a simultaneous decrease in the Severity of Alopecia Tool (SALT) score after 3 months. The report suggests that nemolizumab may suppress the JAK–STAT pathway, potentially improving AA, although its use is only approved for severe AD. This single case highlights the potential benefit of controlling AD activity for managing coexisting AA, though the improvement in AA could be coincidental.
October 2020 in “Veterinary Dermatology” New treatments and diagnostic methods for various animal skin conditions showed promising results.
59 citations
,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
January 2022 in “Dermatology Review” Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.